BioNTech, as my readers will know, was founded as a cancer treatment company. But why did none of its experimental cancer drugs ever make it to a large-scale Phase 3 clinical trial? Why was one of its Phase 2 trials “prematurely ended”? Could it have been that the company’s mRNA-based therapies were in fact accelerating cancers rather than reversing them? Germany’s vaccine and medicines regulator, the PEI, undoubtedly knows. Why shouldn’t we?
Has to be a safety signal, nothing else could explain an abrupt ending.